New delivery method boosts efficiency of CRISPR genome-editing system
The genome-editing technique known as CRISPR allows scientists to clip a specific DNA sequence and replace it with a new one, offering the potential to cure diseases caused by defective genes. For this potential to be realized, however, scientists must find a way to safely deliver the CRISPR machinery and a corrected copy of the DNA into the diseased cells.
MIT researchers have now developed a way to deliver the CRISPR genome repair components more efficiently than previously possible, and they also believe it may be safer for human use. In a study of mice, they found that they could correct the mutated gene that causes a rare liver disorder, in 6 percent of liver cells — enough to cure the mice of the disease, known as tyrosinemia.
“This finding really excites us because it makes us think that this is a gene repair system that could be used to treat a range of diseases — not just tyrosinemia but others as well,” says Daniel Anderson, associate professor in MIT’s Department of Chemical Engineering and a member of MIT’s Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science (IMES).
Anderson is one of the senior authors of a paper describing the findings in the Feb. 1 issue of Nature Biotechnology. Wen Xue, an assistant professor in molecular medicine at the University of Massachusetts Medical School, is also a senior author. The paper’s lead author is Hao Yin, a research scientist at the Koch Institute.
Find and replace
The CRISPR system relies on cellular machinery that bacteria use to defend themselves from viral infection. Researchers have previously harnessed this system to create gene-editing complexes composed of a DNA-cutting enzyme called Cas9 and a short RNA that guides the enzyme to a specific area of the genome, directing Cas9 where to make its cut.
When Cas9 and the short guide RNA targeting a disease gene are delivered into cells, a specific cut is made in the genome, and the cells’ DNA repair processes glue the cut back together, often deleting a small portion of the genome. However, if a corrected copy of the gene is also delivered when the cut is made, the DNA repair can lead to correction of the disease gene, permanently repairing the genome.
In 2014, Anderson and colleagues described the first use of CRISPR to repair a disease gene in an adult animal. In that study, they were able to cure tyrosinemia in mice. However, delivery of the genetic components required a high-pressure injection, a method that can also cause some damage to the liver.
“That was the first demonstration of using CRISPR/Cas9 to do genetic repair in an adult animal,” Anderson says. “We were excited by this demonstration but wanted to find a way to develop a drug form of the repair machinery that would be both safer and more efficient.”
The researchers also wanted to boost the percentage of cells that had the defective gene replaced. In the previous study, about one in 250 liver cells were repaired, which was enough to successfully treat tyrosinemia. However, for many other diseases, a higher percentage of repair would be needed to provide a therapeutic effect.
In the new study, Anderson and colleagues developed a combined nanoparticle and viral delivery system to deliver the CRISPR repair machinery. First, they created a nanoparticle from lipids and messenger RNA (mRNA) that encoded the Cas9 enzyme. The other two components — the RNA guide strand and the DNA for the corrected gene — were embedded into a reprogrammed viral particle based on an adeno-associated virus (AAV).
The researchers first injected the virus about a week before the lipid nanoparticles, giving the liver cells time to begin producing the RNA guide strand and the DNA template. When the nanoparticles carrying the Cas9 mRNA strand were injected, the cells began producing the Cas9 protein, but only for a few days because the mRNA eventually degraded. This is long enough to perform gene repair, but prevents cas9 from lingering in the cells and potentially disrupting other parts of the cells’ genome.
“There’s some concern that if you had Cas9 in your cells for too long of a period of time, it might cause some genomic instability,” Anderson says. “We think the use of the mRNA nanoparticle provides an additional level of safety by making sure the enzyme is not present for too long a period of time.”
With this method, about one in 16 cells had the gene corrected, a 15-fold improvement over the 2014 study. The researchers also found that this approach generated less off-target DNA cutting than methods in which the Cas9 gene is integrated into a cell’s genome.
“We did a genome-scale analysis and we have a very high level of on-target effects but almost no off-target effects,” Yin says.
“This is quite a promising development,” says Terence Flotte, dean of the University of Massachusetts Medical School, who was not part of the research team. “This combination of two different delivery modalities solves a number of hurdles that would otherwise make it difficult to do a gene correction in hepatocytes.”
Read more: Curing disease by repairing faulty genes
The Latest on: CRISPR
via Google News
The Latest on: CRISPR
- Mitigation of off-target toxicity in CRISPR-Cas9 screens for essential non-coding elementson September 6, 2019 at 2:22 am
Pooled CRISPR-Cas9 screens are a powerful method for functionally characterizing regulatory elements in the non-coding genome, but off-target effects in these experiments have not been systematically ...
- CRISPR-Cas9-based mutagenesis frequently provokes on-target mRNA misregulationon September 6, 2019 at 2:13 am
The introduction of insertion-deletions (INDELs) by non-homologous end-joining (NHEJ) pathway underlies the mechanistic basis of CRISPR-Cas9-directed genome editing. Selective gene ablation using ...
- Cellular Computers Get a Boost With CRISPRon September 4, 2019 at 7:27 am
Cancer’s impenetrable secrets partly rely on its mysterious molecular history. As cells turn to the dark side, a whirlwind of DNA changes gradually accumulate. Like flipping multiple interlinked light ...
- A CRISPR Doyen Discusses Gene-Editing Challengeson September 4, 2019 at 5:32 am
Jennifer Doudna, winner of the 2018 Kavli Prize in Nanoscience, talks to Scientific American about what it’s like to work in perhaps the hottest research area in all of biology. She also discusses the ...
- Novel CRISPR method identifies key genes for Toxoplasma survivalon September 3, 2019 at 6:22 am
Using a new approach to genetic screening with CRISPR, researchers at the Crick have identified key genes for the survival of the parasite Toxoplasma gondii in mice. CRISPR screening is an ...
- Four U.S. CRISPR Trials Editing Human DNA to Research New Treatmentson September 3, 2019 at 5:06 am
Last fall, the birth of genetically edited twin girls in China—the world’s first “designer babies”—prompted an immediate outcry in the medical science community. The change to the twins’ genomes, ...
- University of California granted new U.S. CRISPR-Cas9 patent related to single-guide RNAon September 2, 2019 at 9:46 pm
University's 12th U.S. patent adds new compositions for CRISPR-Cas9 gene-editing technology to overall patent portfolio; expects to add five more patents in near future BERKELEY, Calif., Sept.
- CRISPR could lead to gene-editing fix for a form of male infertilityon September 1, 2019 at 4:55 am
Male mice with a mutation that prevented them producing any sperm have fathered offspring the natural way after a team in China fixed their infertility by CRISPR genome editing. The technique could ...
- Giant virus has evolved its own kind of CRISPR to destroy invaderson September 1, 2019 at 12:22 am
The mimivirus is so enormous it has its own kind of CRISPR-like immune system to defend against the smaller viruses that attack it. A team in France has confirmed how it works by transferring the ...
- BRIEF-Crispr Therapeutics AG May Offer And Sell From Time To Time Its Common Shares Having Aggregate Offering Price Of Up To $200 Millionon August 30, 2019 at 1:39 pm
Aug 30 (Reuters) - CRISPR Therapeutics AG: * CRISPR THERAPEUTICS AG - MAY OFFER AND SELL FROM TIME TO TIME ITS COMMON SHARES HAVING AGGREGATE OFFERING PRICE OF UP TO $200 MILLION * CRISPR THERAPEUTICS ...
via Bing News